21 Sep 2018 | 8:28 AM
Research Report

Equity Research Report: Master Pick-Lupin Ltd

Lupin has a strong pipeline of complex generics in the US, mainly in oral contraceptives and ophthalmics, which it intends to launch in the coming years. This should help to sustain its revenue growth trajectory. While most of this growth is expected to be organic, the company also has plans to grow inorganically, which will help to enter new markets.
24 Apr 2015 | 06:00 PM

After forming record high at 2115 in early April, 2015, it witnessed profit taking and retraced to major support zone of 100 days EMA, which currently lies around 1690. It has been consolidating around that zone for nearly a week and formed a fresh buying pivot. So, participants may accumulate it in the given range of 1745-1758 with close below stop loss of 1630 for target of 2020.